Specialty Research, (“SRI”), headquartered in San Antonio, Texas, was formed to acquire leading contract research organizations (CRO’s) focused on specialty therapeutic areas such as endocrinology. The first acquisition of SRI, Diabetes & Glandular Disease Research Associates (DGD) specializes in providing Phase I and II/III clinical research investigative services to prominent pharmaceutical and biotechnology companies focused on diabetes, obesity and other endocrine and metabolic therapeutic areas.

Date of Realization:  December 2011

Industry Sector:  Healthcare Services, Medical Devices and Life Sciences

Fund: III